Tokai Adds $23M to Series D, Preps Prostate Drug for Trial
By Trista Morrison
Tuesday, September 20, 2011
Tokai Pharmaceuticals Inc. is expected to announce Tuesday that it has raised $23 million in a Series D follow-on round to fund Phase IIb trials of triple-acting prostate cancer drug galeterone (TOK-001).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.